Milestone combines a strong liquidity position with a clearly focused, differentiated product strategy. The company holds net cash, has ample short-term resources, and operates an asset-light model. Clinically, CARDAMYST is first-in-class for at-home PSVT treatment, supported by robust patents and a patient-centric value proposition. R&D efforts are coherent, with follow-on indications that build on the same scientific and commercial foundation.

The main risks center on continued operating losses, dependence on a single lead asset, and the need for ongoing external financing until revenue becomes meaningful. Commercial execution risk is high: physician adoption, payer coverage, and patient uptake of an at-home PSVT therapy must all align. Competition from established hospital treatments, invasive procedures, and potential future entrants further adds uncertainty. The long history of losses also underscores that the path to sustainable profitability is still unproven.

Milestone appears to be at an inflection point, transitioning from a pure development-stage biotech toward a commercial-stage company built around CARDAMYST and the broader etripamil franchise. In the near to medium term, financials are likely to remain dominated by cash burn and investment rather than profits. The company’s future trajectory will largely depend on the pace and breadth of CARDAMYST adoption, the success of AFib-RVR and pediatric PSVT programs, and its ability to maintain sufficient funding through this commercialization and clinical expansion phase.